Carén Helena, Abel Frida, Kogner Per, Martinsson Tommy
Department of Clinical Genetics, Institute of Biomedicine, University of Gothenburg, Sahlgrenska University Hospital, SE-41345 Göteborg, Sweden.
Biochem J. 2008 Dec 1;416(2):153-9. doi: 10.1042/bj20081834.
ALK (anaplastic lymphoma kinase) is oncogenic in several tumours and has recently been identified as a predisposition gene for familial NB (neuroblastoma) harbouring mutations in the TKD (tyrosine kinase domain). We have analysed a large set of sporadic human NB primary tumours of all clinical stages for chromosomal re-arrangements using a CGH (comparative genomic hybridization) array (n=108) and mutations of the ALK gene (n=90), and expression of ALK and related genes (n=19). ALK amplification or in-gene re-arrangements were found in 5% of NB tumours and mutations were found in 11%, including two novel not previously published mutations in the TKD, c.3733T>A and c.3735C>A. DNA mutations in the TKD and gene amplifications were only found in advanced large primary tumours or metastatic tumours, and correlated with the expression levels of ALK and downstream genes as well as other unfavourable features, and poor outcome. The results of the present study support that the ALK protein contributes to NB oncogenesis providing a highly interesting putative therapeutic target in a subset of unfavourable NB tumours.
间变性淋巴瘤激酶(ALK)在多种肿瘤中具有致癌性,最近被确定为携带酪氨酸激酶结构域(TKD)突变的家族性神经母细胞瘤(NB)的一个易感基因。我们使用比较基因组杂交(CGH)芯片分析了一大组所有临床分期的散发性人类NB原发性肿瘤的染色体重排(n = 108)以及ALK基因的突变(n = 90),并检测了ALK及相关基因的表达(n = 19)。在5%的NB肿瘤中发现了ALK扩增或基因内重排,11%的肿瘤发现了突变,包括TKD中两个此前未发表的新突变,即c.3733T>A和c.3735C>A。TKD中的DNA突变和基因扩增仅在晚期大的原发性肿瘤或转移性肿瘤中发现,并且与ALK及下游基因的表达水平以及其他不良特征相关,预后较差。本研究结果支持ALK蛋白在NB肿瘤发生中起作用,为一部分不良NB肿瘤提供了一个非常有吸引力的潜在治疗靶点。